Updates From the International AIDS Conference (IAS 2019)

Slides:

Advertisements

Similar presentations

Update: National AIDS Programmes FHI, Horizons, HHS-CDC & HRSA, Macro, Measure, Synergy, USAID, WHO,UNAIDS Katherine Marconi, Ph.D., MS Presenter A Guide.

Advertisements

Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.

IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.

DR CHIDI V NWENEKA EXECUTIVE DIRECTOR AFRICAN AIDS VACCINE PARTNERSHIP AAVP and the Promotion of HIV Vaccines in Africa: Supporting Career Development.

I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.

Interamerican College of Physicians and Surgeons.

Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.

Title of Presentation Speaker Names, Credentials, Full Title Collaborative Family Healthcare Association 17 th Annual Conference October 15-17, 2015 Portland,

ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.

Submitting assignments to TURNITIN.COM You need to login and create an account at using the following info: Class ID Password---v5micro05.

Calculating Postsecondary Costs 6 th Grade Postsecondary Costs #4.

Diagnostics - More than 100 years old Drugs – Last drug 40 years old Vaccine – Nearly 90 years old Lucica Ditiu Executive Secretary, Stop TB Partnership.

Oklahoma Nurses Association is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American.

Appropriate Evaluation & Treatment of UTI in the Elderly Final Workshop June 17, 2014.

Speaker Disclosure Explanation

Title of Presentation Speaker Names, Credentials, Full Title Collaborative Family Healthcare Association 13 th Annual Conference October 27-29, 2011 Philadelphia,

Following the Yellow Brick Road to the Emerald City of Patient Care Coordination On a Budget Cortney McDuff, RN Cindy McHenry, RN BSN.

Understanding the Rationale of the 2015 WHO Guidelines on PrEP IAS Satellite Session Heather Watts M.D. Office of the Global AIDS Coordinator July 18,

Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.

Harry Lampiris, MD, Moderator Chief, ID Section, Medical Service, SFVAMC Professor of Clinical Medicine, UCSF.

Women and Clinical Trials (presented in Haitian Creole) Welcome!

What’s Next – and When: An Update on Injectable Prevention

Faculty Disclosure Information

New/Optimal ARV Treatments Why ? & How

Heart Failure Management

David Magnuson, Trevor Hawkins, Robertino Mera

22th International AIDS Conference

Managing Women Living With HIV Infection

Speaker Names, Credentials, Full Title

CathPCI-NCDR Registry Mortality (STEMI)

The Brazilian Experience

Antiretroviral Updates: New Treatments for HIV

Behavioral and Social Science in Biomedical HIV Research

Family Medicine Grand Rounds University of Washington TITLE

Faculty & Staff Promotion and Tenure Workshop Monday, April 16, 2018

Botswana Moving Forward with DTG

Translating Emerging HIV Data Into Clinical Practice

مقدمه ای بر مهارت های زندگی

The Politics of PrEP The French Experience

آموزش همسان دکتر كامبيز محضري.

Why Dolutegravir? Daniel R. Kuritzkes, M.D.

How it was possible to offer Integrase Inhibitor as first line ART while maintaining the sustainability of the Brazilian policy of universal access to.

Update From Seattle 2017.

Speaker Names, Credentials, Full Title

Building the Community Response to the Dolutegravir Safety Signal

April 11, :00-10:00 a.m. PT/ 12:00-1:00 p.m. ET

HIV Update 2018: A Front Row Seat

Division of AIDS Office of the Director Workforce Operations,

ART Options and Treatment Decisions for Women of Reproductive Potential

4 + (-5) = A. Start at zero B. Move ______ spaces ___________ to get to the first number. C. From there, move _____ spaces __________ D. My final answer.

Updates From CROI 2019: Treatment of HIV and Its Complications

Medical Management of HIV Among Transgender Adults

TRANSITION TO TLD – ZIMBABWE REPORT

Investigational Antiretroviral Strategies and Drugs

Investigational Approaches to Antiretroviral Therapy

Safety and PK of Subcutaneous GS-6207, a Novel HIV-1 Capsid Inhibitor

Housekeeping: CME Information Accreditation & Designation Statements

Faculty & Staff Promotion and Tenure Workshop Monday, April 8, 2019

Investigational Approaches to Antiretroviral Therapy

Excellence in TB Control Award

Dolutegravir in PEPFAR

Data Hub for Asia-Pacific Review in slides Singapore

2025 AIDS Targets: Next Steps

Dual vs. Triple ART: What to start?

Intercompany and Interfund Processing in Dynamics GP

Important Reminders Mutual of Omaha FAQ’s

Managing Syphilis in HIV Co-infected Patients: A Case-Based Approach

The IAS TB/HIV Research Prizes are awarded to:

Presentation transcript:

Updates From the International AIDS Conference (IAS 2019)

Updates From the International AIDS Conference (IAS 2019)

CME Information

Nursing and Pharmacy Credits

Evaluations will be available in your IAS-USA “My Activities” page by 5 pm PT today. See the IAS–USA website for instructions on claiming CME, pharmacy, nursing, or pharmacotherapy credits, or a certificate of participation.

Grant Support for this Webinar

Navigating the Webinar

Poll 1

Poll 2

Poll 3

Updates From the International AIDS Conference (IAS 2019)

Financial Relationships With Commercial Entities

Learning Objectives

Pretest Question 1

Pretest Question 2

HIV/AIDS Epidemiology

WHO 2019 Annual Report

WHO 2019 Annual Report

WHO 2019 Annual Report

WHO 2019 Annual Report

WHO 2019 Annual Report

IAS 2019

ART – Initial Therapy

ADVANCE

ADVANCE: Weight Gain

GEMINI: Initial ART with DTG/3TC

REFLATE: Initial ART with TB

TSEPAMO: DTG + Neural Tube Defects (NTD)

DTG + Neural Tube Defects (NTD): Additional Data

WHO: Updated ART Recommendations (7/22/19)

ART -- Switch/Maintenance

Study 380-4030: Switch

ART Switch in Women

TANGO: Switch to DTG/3TC

DUALIS: Switch to DTG + Boosted DRV

CAB+RPV IM: ATLAS and FLAIR Pooled Analysis (1)

CAB+RPV IM: ATLAS and FLAIR Pooled Analysis (2)

CAB+RPV IM: ATLAS and FLAIR Pooled Analysis (3)

QUATUOR (ANRS 170)

ART -- New Drugs

Islatravir (ISL; MK-8591; EFdA)

Islatravir (MK-8591; EFdA)

Islatravir (MK-8591; EFdA)

Islatravir (MK-8591; EFdA)

Islatravir (MK-8591; EFdA)

Islatravir (MK-8591; EFdA)

Fostemsavir (FTR): Oral HIV Attachment Inhibitor

Fostemsavir (FTR): Oral Attachment Inhibitor

HIV Capsid Inhibitors

Capsid Inhibitor: GS-6207

Capsid Inhibitor: GS-6207

Capsid Inhibitor: GS-6207

ART -- Prevention

On-Demand PrEP: Prevenir INTERIM REPORT

DISCOVER: PrEP with TAF/FTC vs. TDF/FTC

Islatravir Implant

Islatravir Implant

Islatravir Implant

HIV Vaccine Study: ASCENT (HPX2003/HVTN 118)

HIV Vaccine Study: ASCENT (HPX2003/HVTN 118)

HIV Vaccine Study: Next Steps

Acknowledgments

Posttest Question 1

Posttest Question 2

Question-and-Answer

Evaluations will be available in your IAS-USA “My Activities” page by 5 pm PT today. See the IAS–USA website for instructions on claiming CME, pharmacy, nursing, or pharmacotherapy credits, or a certificate of participation.

Final Poll

Thank You